Neogenomics Inc 8-K, filed Apr 15, 2021
Neogenomics Inc (NEO)
8-K
2021-04-15
For: 2021-04-15
View Original
Added on
July 08, 2026
About this 8-K
Neogenomics Inc filed this 8-K on April 15, 2021.
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
| (Address of principal executive offices) | (Zip Code) | ||||||||||||||||
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||||||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||||||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||||||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||||||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01 | Other Events. | ||||
Annual Report and Letter to Shareholders
On April 15, 2021, the 2020 Annual Report and Letter to Shareholders, dated April 15, 2021, was made available to shareholders of the Company, along with the definitive proxy material, and is attached hereto as Exhibit 99.1.
This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
| Item 9.01 | Exhibits. | ||||
(d) Exhibits.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NEOGENOMICS, INC. | ||||||||
By: | /s/ Kathryn B. McKenzie | |||||||
| Kathryn B. McKenzie | ||||||||
| Chief Financial Officer | ||||||||
| April 15, 2021 | ||||||||
2020 | Exhibit 99.1
Key 2020 Financial Highlights and Accomplishments OUR COMMON PURPOSE We save lives by improving patient care. OUR VISION By providing uncompromising quality, exceptional service and innovative solutions, we are becoming the world’s leading cancer testing and information company. OUR VALUES Quality, Integrity, Accountability, Teamwork, and Innovation Becoming the World’s Leading Cancer Testing and Information Company
Clinical Tests Performed(3) (in thousands) Pharma Revenue and Backlog (in millions) $ in Thousands 2018 2019 2020 Revenue $276,741 $408,830 $444,448 % Growth 15.2% 47.7% 8.7% Adjusted EBITDA (Non-GAAP)(1) $43,552 $57,217 $34,842 % Growth (Decline) 29.6% 31.4% (39.1%) Net Income $2,640 $8,006 $4,172 Clinical Testing Volume(2) 749,902 987,539 976,069 % Growth (Decline) 14.1% 31.7% (1.2%) Revenue, Adjusted EBITDA, Net Income and Clinical Testing Volume
Dear Fellow Shareholders:
Dear Fellow Shareholders (cont.)
Douglas M. VanOort Chairman of the Board of Directors and Chief Executive Officer
Critical Success Factors and Actions 2021 Focus: Sustainable Growth Contribute and Connect Empower Employees and Provide Meaningful Work Experiences Improve Quality, Efficiency and Productivity Build New Products and Capabilities Consistently Achieve TAT Goals Build Sustainable Organization Transform IT Make Informatics Enterprise-wide Be a Market Leader in NGS World-Class Culture Uncompromising Quality and Exceptional Service Innovation and Growth Employee Engagement Employee Retention >88% Customer Satisfaction Client Retention >95% Shareholder Satisfaction Achieve Results >Plan Satisfaction Model COMMON PURPOSE We save lives by improving patient care. VISION By providing uncompromising quality, exceptional service and innovative solutions, we are becoming the world’s leading cancer testing and information company. VALUES Quality, Integrity, Accountability, Teamwork, Innovation.
Board of Directors Douglas M. VanOort Chairman and CEO Lynn A. Tetrault Lead Director Bruce K. Crowther Director Alison L. Hannah, M.D. Director Raymond R. Hipp Director Kevin C. Johnson Director Steven C. Jones Director Stephen M. Kanovsky Director Michael A. Kelly Director Rachel A. Stahler Director Corporate Offices Transfer Agent Independent Registered Public Accounting Firm Annual Meeting Stock Listing and Information Forward Looking Statements Corporate Information Corporate Officers Kathryn B. McKenzie Chief Financial Officer Denise E. Pedulla General Counsel and Corporate Secretary Robert J. Shovlin President, Clinical Services George A. Cardoza President, Pharma Services William B. Bonello President, Informatics Douglas M. Brown Chief Strategy and Corporate Development Officer Cynthia J. Dieter Chief Accounting Officer and Controller Jennifer M. Balliet Chief Culture Officer Stephanie K. Bywater Chief Compliance Officer Marcus B. Silva Chief Marketing Officer Medical Leadership Lawrence M. Weiss, M.D. Chief Medical Officer Sally S. Agersborg, M.D., Ph.D. Medical Director, Aliso Viejo, California Derek Lyle, M.D. Medical Director, Carlsbad, California and Fort Myers, Florida J. Christopher Mixon, M.D. Laboratory Director, Nashville, Tennessee David L. Morgan, M.D. Laboratory Director, Houston, Texas Yin Xu, M.D., Ph.D. Medical Director, Atlanta, Georgia Josette William Ragheb, M.D., Ph.D. Global Medical Director, Pharma Services
NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing, partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, immunohistochemistry, and morphologic analysis through our nation-wide network of CAP-accredited, CLIA-certified laboratories. Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.